Advanced Oncotherapy #AVO receives first part of Yantai distribution agreement payment

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the Company’s announcement of 3 April 2018, the Company has received from Yantai Cipu, through its affiliated entity Liquid Harmony, £6.5 million as the first payment relating to the Distribution Agreement announced on 7 December 2017. The […]

Advanced Oncotherapy #AVO – Update on Distribution Agreement

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that discussions between Yantai Cipu, through its affiliated entity Liquid Harmony, and a major medical equipment and pharmaceutical distribution company in China are continuing beyond the previously announced date of 31 March 2018.  As announced on 16 February 2018, Yantai Cipu informed […]

Advanced Oncotherapy #AVO – Completion of the Subscription Agreement

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that in relation to the announcement dated 7 December 2017 and following the passing of the resolution proposed for the vote of the Company’ shareholders on 23 January 2018, the Company has been informed by Yantai Cipu that the Chinese […]

Advanced Oncotherapy #AVO – Notice of General Meeting

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that a circular convening the Company’s General Meeting to be held at the Royal Institute of British Architects, 66 Portland Place, London W1B 1AD at 10:00am on Tuesday, 23 January 2018, in relation to the transactions announced on 7 December 2017 has […]

Nicolas Serandour, CEO of Advanced Oncotherapy #AVO discusses Yantai deal & £37m equity investment with BRR Media

Nicolas Serandour, CEO of Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, announces that they have signed an exclusive distribution agreement with Yantai CIPU Medical Technology to market and sell Advanced Oncotherapy’s LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea. At the same time, the Company has secured £20.9 […]

Advanced Oncotherapy #AVO – Exclusive distribution agreement for China and other geographies & new equity investments for a total consideration of £37m

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed an exclusive distribution agreement with Yantai CIPU Medical Technology Co. Ltd. to market and sell Advanced Oncotherapy’s LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea. Under the agreement, Yantai CIPU will make a payment of £16.5 […]